Virios Therapeutics (VIRI) Insider Trading & Ownership $1.87 -0.06 (-3.11%) As of 01/17/2025 Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends Virios Therapeutics (NASDAQ:VIRI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.20%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$193,112.52Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$468.00 Get VIRI Insider Trade Alerts Want to know when executives and insiders are buying or selling Virios Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VIRI Insider Buying and Selling by Quarter Virios Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/21/2023William PridgenDirectorBuy15,335$1.30$19,935.50 8/17/2023Gregory Scott DuncanCEOBuy25,000$1.25$31,250.00 12/8/2022Richard James WhitleyDirectorSell1,800$0.26$468.00 5/23/2022Angela WalshSVPBuy2,000$4.58$9,160.00 5/23/2022Gregory Scott DuncanCEOBuy7,500$4.52$33,900.00 5/17/2022William PridgenDirectorBuy13,450$4.38$58,911.00 3/29/2022William PridgenDirectorBuy600$4.94$2,964.00 3/23/2022William PridgenDirectorBuy2,197$5.46$11,995.62 1/27/2022William PridgenDirectorBuy4,180$5.98$24,996.40 (Data available from 1/1/2013 forward) VIRI Insider Trading Activity - Frequently Asked Questions Who is on Virios Therapeutics's Insider Roster? The list of insiders at Virios Therapeutics includes Angela Walsh, Gregory Scott Duncan, Richard James Whitley, and William Pridgen. Learn more on insiders at VIRI. What percentage of Virios Therapeutics stock is owned by insiders? 12.20% of Virios Therapeutics stock is owned by insiders. Learn more on VIRI's insider holdings. Which Virios Therapeutics insiders have been buying company stock? The following insiders have purchased VIRI shares in the last 24 months: Gregory Scott Duncan ($31,250.00), and William Pridgen ($19,935.50). How much insider buying is happening at Virios Therapeutics? Insiders have purchased a total of 40,335 VIRI shares in the last 24 months for a total of $51,185.50 bought. Virios Therapeutics Key ExecutivesMr. Gregory Duncan (Age 59)Chairman & CEO Compensation: $566.92kDr. William L. Pridgen M.D. (Age 63)Founder & Director Compensation: $35kMs. Angela Walsh (Age 57)CFO, SVP of Finance, Corporate Secretary & Treasurer Compensation: $282.64kDr. R. Michael Gendreau M.D. (Age 68)Ph.D., Chief Medical Officer Compensation: $364.94kMr. Ralph D. Grosswald M.P.H. (Age 55)Senior Vice President of Operations Compensation: $274.69kMs. Carol Duffy Ph.D.Chief Scientific Advisor More Insider Trading Tools from MarketBeat Related Companies Inhibikase Therapeutics Insider Selling Cardiff Oncology Insider Selling Aclaris Therapeutics Insider Selling scPharmaceuticals Insider Selling Alector Insider Selling Lyell Immunopharma Insider Selling Acrivon Therapeutics Insider Selling Coherus BioSciences Insider Selling ADC Therapeutics Insider Selling Vaxart Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:VIRI) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
